Epclusa
Velpatasvir and Sofosbuvir
- Strength
- 200 mg/1, 50 mg/1
- Form
- Pellet
- Class
- Hepatitis C Virus NS5A Inhibitor; Hepat…
Gilead Sciences, Inc.
Not stocked by us — reference only
Velpatasvir and Sofosbuvir
Listed by Asegua Therapeutics LLC
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor |
| Approval route | Authorised generic |
| NDC code | 72626-2701 |
| FDA application | NDA208341 |
| RxNorm concept | 1799212 |
| Package sizes listed | 1 |
| Marketed since | November 2018 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Velpatasvir and Sofosbuvir
Gilead Sciences, Inc.
Not stocked by us — reference only
Velpatasvir and Sofosbuvir
Gilead Sciences, Inc.
Not stocked by us — reference only
Velpatasvir and Sofosbuvir
Gilead Sciences, Inc.
Not stocked by us — reference only
Velpatasvir and Sofosbuvir
Gilead Sciences, Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.